-
-
-
-
-
-
-
Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities
-
-
-
-
-
-
-
Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation
-
-
-
-
-
-
-
Harmony reports Q2 revenue growth, reaffirms 2025 guidance
-
-
-
-
-
-
-
Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $70 at H.C. Wainwright
-
-
-
-
-
-
-
HARMONY BIOSCIENCES REPORTS STRONG THIRD QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS CATALYST-RICH, LATE-STAGE PIPELINE POISED TO DELIVER ONE OR MORE NEW LAUNCHES EVERY YEAR OVER NEXT FIVE YEARS
-
-
-
-
-
-
-
Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wak
-
-
-
-
-
-
-
HARMONY BIOSCIENCES TO PRESENT RESULTS FROM BEHAVIORAL STUDY IN 22Q11.2 DELETION SYNDROME AT AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY ANNUAL MEETING
-
1,231,050 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


